Comparing a new bladder chemotherapy combination to standard care
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares a new combination of chemotherapy drugs delivered directly into the bladder versus standard treatment for people with non-muscle invasive bladder cancer that has returned or not responded to prior therapy. It aims to see if the new treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of non-muscle invasive bladder cancer (cancer that hasn't spread into the bladder muscle).
- You must be willing to undergo regular bladder checks (cystoscopy) and possibly surgery to remove tumors during the study.
- You must have had all visible bladder tumors completely removed before starting the study.
- You must have been previously treated for bladder cancer, and it may have come back or not responded to treatment (like BCG therapy).
- You must not have cancer that has spread beyond the bladder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.